Hansen's Disease Treatment
For Hansen's disease (leprosy), use WHO multidrug therapy (MDT): paucibacillary disease requires 6 months of rifampin 600mg monthly (supervised) plus dapsone 100mg daily (self-administered), while multibacillary disease requires 12 months of rifampin 600mg monthly (supervised), clofazimine 300mg monthly (supervised) plus 50mg daily (self-administered), and dapsone 100mg daily (self-administered).
Classification and Treatment Selection
The first critical step is determining whether the patient has paucibacillary (PB) or multibacillary (MB) disease, as this dictates treatment duration and regimen complexity 1, 2.
Paucibacillary (PB) Leprosy
- Duration: 6 months of treatment 3, 2
- Regimen:
- Rifampin 600mg once monthly (supervised dose)
- Dapsone 100mg daily (self-administered)
Multibacillary (MB) Leprosy
- Duration: 12 months of treatment 2, 4
- Regimen:
- Rifampin 600mg once monthly (supervised)
- Clofazimine 300mg once monthly (supervised) plus 50mg daily (self-administered)
- Dapsone 100mg daily (self-administered)
Key Clinical Considerations
Fixed-duration therapy is standard: Treatment continues for the specified duration regardless of clinical clearance or bacterial status 3. Research shows that 76.7% of PB patients have residual patches at treatment completion, but only 7% show histological evidence of active disease 3.
Leprosy reactions require immediate intervention: Both Type 1 (reversal reactions) and Type 2 (erythema nodosum leprosum) reactions can cause rapid, irreversible nerve damage 1. Continue MDT while adding anti-inflammatory treatment—typically corticosteroids for acute reactions.
Nerve damage is irreversible: Prevention through early treatment is the only effective strategy 1. Monitor nerve function throughout treatment, as subclinical neuropathy can be detected through nerve conduction studies.
Alternative Regimens
For patients unable to tolerate standard MDT, an alternative monthly regimen of rifampin, moxifloxacin, and minocycline has shown promise 5. However, this lacks the extensive validation of WHO-recommended therapy and should be reserved for cases with documented intolerance to standard drugs.
The evidence from older studies examining daily rifampin regimens 6, 7 has been superseded by the current WHO fixed-duration monthly supervised approach, which balances efficacy with feasibility and adherence.
Common Pitfalls
Do not stop treatment early: Even if lesions appear to resolve, complete the full 6-month (PB) or 12-month (MB) course 3, 2.
Do not confuse leprosy reactions with treatment failure: Reactions can occur during or after treatment and require anti-inflammatory therapy while continuing MDT 1.
Monitor for side effects: Dapsone can cause dose-related hemolysis (especially in G6PD deficiency), clofazimine causes pink-to-brownish skin discoloration and ichthyosis 8, 6, and rifampin can cause hepatotoxicity.
Adjunctive Management
Neuropathic pain requires specific treatment with pregabalin or amitriptyline 1. Rehabilitation, orthoses, and prostheses address established deformities. Collaboration between dermatology and physical medicine is essential for comprehensive care 1.